JPWO2020041344A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020041344A5 JPWO2020041344A5 JP2021509910A JP2021509910A JPWO2020041344A5 JP WO2020041344 A5 JPWO2020041344 A5 JP WO2020041344A5 JP 2021509910 A JP2021509910 A JP 2021509910A JP 2021509910 A JP2021509910 A JP 2021509910A JP WO2020041344 A5 JPWO2020041344 A5 JP WO2020041344A5
- Authority
- JP
- Japan
- Prior art keywords
- och
- cooh
- alkyl
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 8
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 6
- 208000027559 Appetite disease Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719938P | 2018-08-20 | 2018-08-20 | |
| US62/719,938 | 2018-08-20 | ||
| PCT/US2019/047309 WO2020041344A1 (en) | 2018-08-20 | 2019-08-20 | Methods and compositions for drugs to treat ophthalmic diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534202A JP2021534202A (ja) | 2021-12-09 |
| JPWO2020041344A5 true JPWO2020041344A5 (https=) | 2022-08-26 |
| JP2021534202A5 JP2021534202A5 (https=) | 2022-08-26 |
Family
ID=69591159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509910A Pending JP2021534202A (ja) | 2018-08-20 | 2019-08-20 | 眼科疾患を処置する為の薬物の為の方法及び組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12221447B2 (https=) |
| EP (1) | EP3840745A4 (https=) |
| JP (1) | JP2021534202A (https=) |
| KR (1) | KR20210049857A (https=) |
| CN (1) | CN112654353A (https=) |
| AU (1) | AU2019326448A1 (https=) |
| BR (1) | BR112021003189A2 (https=) |
| CA (1) | CA3109809A1 (https=) |
| CO (1) | CO2021003607A2 (https=) |
| IL (1) | IL280952A (https=) |
| MX (1) | MX2021002028A (https=) |
| SG (1) | SG11202101522WA (https=) |
| TW (1) | TW202021968A (https=) |
| WO (1) | WO2020041344A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019326448A1 (en) | 2018-08-20 | 2021-03-11 | Duke University | Methods and compositions for drugs to treat ophthalmic diseases |
| WO2024257328A1 (ja) * | 2023-06-16 | 2024-12-19 | 千寿製薬株式会社 | 眼疾患モデル動物 |
| JP7776899B1 (ja) * | 2024-06-14 | 2025-11-27 | 株式会社坪田ラボ | 局所投与用の重症眼表面疾患の処置剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4153693B2 (ja) | 2001-04-25 | 2008-09-24 | 大日本住友製薬株式会社 | 新規なＣａＭＫＫ阻害剤 |
| GB0600763D0 (en) | 2006-01-13 | 2006-02-22 | Crysoptix Ltd | 6, 7-dihydrobenzimidazo[1,2-C]quininazolin-6-one carboxylic acid, its esters and method of synthesis thereof |
| GB0600764D0 (en) * | 2006-01-13 | 2006-02-22 | Crysoptix Ltd | Organic compound, optical crystal film and method of production thereof |
| US8207185B2 (en) | 2006-10-12 | 2012-06-26 | Duke University | CaMKKβ as a target for treating obesity |
| JP5464395B2 (ja) | 2008-02-01 | 2014-04-09 | 大陽日酸株式会社 | 重水素化された芳香環又は複素環を有する化合物の製造方法 |
| WO2009154754A2 (en) | 2008-06-17 | 2009-12-23 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| WO2010033511A1 (en) | 2008-09-16 | 2010-03-25 | Concert Pharmaceuticals, Inc. | Deuterated 2-amino-3-hydroxypropanoic acid derivatives |
| WO2012024255A2 (en) | 2010-08-16 | 2012-02-23 | Duke University | Camkk-beta as a target for treating cancer |
| WO2012064618A1 (en) * | 2010-11-09 | 2012-05-18 | Crysoptix Kk | Negative dispersion retardation plate and achromatic circular polarizer |
| CN103702961A (zh) | 2011-05-23 | 2014-04-02 | 赛诺菲 | 含有n-烷基的氘代化合物的制备方法 |
| CN104684555A (zh) | 2012-09-18 | 2015-06-03 | 奥斯拜客斯制药有限公司 | 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学 |
| EP2935251A1 (en) | 2012-12-20 | 2015-10-28 | Concert Pharmaceuticals Inc. | Deuterated alk inhibitors |
| AU2014250762A1 (en) | 2013-04-12 | 2015-10-29 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of HCV |
| RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
| AU2019326448A1 (en) | 2018-08-20 | 2021-03-11 | Duke University | Methods and compositions for drugs to treat ophthalmic diseases |
-
2019
- 2019-08-20 AU AU2019326448A patent/AU2019326448A1/en not_active Abandoned
- 2019-08-20 JP JP2021509910A patent/JP2021534202A/ja active Pending
- 2019-08-20 CN CN201980054524.XA patent/CN112654353A/zh active Pending
- 2019-08-20 EP EP19852526.3A patent/EP3840745A4/en active Pending
- 2019-08-20 SG SG11202101522WA patent/SG11202101522WA/en unknown
- 2019-08-20 CA CA3109809A patent/CA3109809A1/en active Pending
- 2019-08-20 US US17/269,830 patent/US12221447B2/en active Active
- 2019-08-20 KR KR1020217008504A patent/KR20210049857A/ko not_active Ceased
- 2019-08-20 TW TW108129703A patent/TW202021968A/zh unknown
- 2019-08-20 BR BR112021003189-8A patent/BR112021003189A2/pt not_active Application Discontinuation
- 2019-08-20 MX MX2021002028A patent/MX2021002028A/es unknown
- 2019-08-20 WO PCT/US2019/047309 patent/WO2020041344A1/en not_active Ceased
-
2021
- 2021-02-18 IL IL280952A patent/IL280952A/en unknown
- 2021-03-19 CO CONC2021/0003607A patent/CO2021003607A2/es unknown
-
2024
- 2024-12-09 US US18/973,967 patent/US20250122209A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015526458A5 (https=) | ||
| KR101986272B1 (ko) | 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도 | |
| JP2019515884A5 (https=) | ||
| JP2015535247A5 (https=) | ||
| WO2011004620A1 (ja) | 細胞保護剤 | |
| JP3852621B2 (ja) | 血管内皮細胞機能改善剤 | |
| JP2021534160A5 (https=) | ||
| KR20210104743A (ko) | 4-페닐부티르산을 함유하는 노시의 치료 또는 예방제 | |
| CN113242736A (zh) | 一种治疗肺动脉高压和相关性肺动脉高压的方法 | |
| JP2014500280A5 (https=) | ||
| JP2007527417A5 (https=) | ||
| JP2021534202A5 (https=) | ||
| JPWO2020041344A5 (https=) | ||
| ES2393271T3 (es) | Agente para la prevención y tratamiento de la insuficiencia renal aguda | |
| JP5017268B2 (ja) | 覚醒を改善する方法 | |
| JP2011144111A (ja) | 軸性近視の予防または治療剤 | |
| WO2020041344A4 (en) | Methods and compositions for drugs to treat ophthalmic diseases | |
| JPWO2023078333A5 (https=) | ||
| KR102701892B1 (ko) | 에르도스테인 유도체 및 이를 함유하는 약학 조성물 | |
| JPH11269171A (ja) | ５―（１，２―ジチオラン―３―イル―）吉草酸（α―リポ酸）またはその生理学的に許容しうる塩を有効成分とする脂肪代謝障害治療剤 | |
| JP2015520759A5 (https=) | ||
| JP4612981B2 (ja) | 高血圧性細動脈障害抑制剤 | |
| JPWO2022086958A5 (https=) | ||
| JPWO2020037152A5 (https=) | ||
| JP7778396B2 (ja) | シロスタゾールを含む組成物の脳血管疾患への応用 |